|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
75
-0.0%
330.23
USD 24,767
|
75
-0.0%
|
330.23
|
USD 24,767
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
967
-0.3%
329.86
USD 318,975
|
967
-0.3%
|
329.86
|
USD 318,975
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
400
-0.1%
328.68
USD 131,472
|
400
-0.1%
|
328.68
|
USD 131,472
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
1,000
-0.3%
327.63
USD 327,627
|
1,000
-0.3%
|
327.63
|
USD 327,627
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
800
-0.2%
325.63
USD 260,501
|
800
-0.2%
|
325.63
|
USD 260,501
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
900
-0.3%
324.69
USD 292,218
|
900
-0.3%
|
324.69
|
USD 292,218
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
1,649
-0.5%
323.47
USD 533,394
|
1,649
-0.5%
|
323.47
|
USD 533,394
|
|
|
2025-03-14 |
2025-03-13 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
1,951
-0.5%
322.45
USD 629,100
|
1,951
-0.5%
|
322.45
|
USD 629,100
|
|
|
2025-03-14 |
2025-03-12 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
200
-0.1%
334.97
USD 66,994
|
200
-0.1%
|
334.97
|
USD 66,994
|
|
|
2025-03-14 |
2025-03-12 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
800
-0.2%
333.66
USD 266,926
|
800
-0.2%
|
333.66
|
USD 266,926
|
|
|
2025-03-14 |
2025-03-12 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
2,382
-0.7%
332.38
USD 791,726
|
2,382
-0.7%
|
332.38
|
USD 791,726
|
|
|
2025-03-14 |
2025-03-12 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
2,759
-0.8%
331.36
USD 914,221
|
2,759
-0.8%
|
331.36
|
USD 914,221
|
|
|
2025-03-14 |
2025-03-12 |
S
Sale
|
CRAVES FRED B
Non-Executive Director
|
1,587
-0.4%
330.54
USD 524,560
|
1,587
-0.4%
|
330.54
|
USD 524,560
|
|
|
2025-03-12 |
2025-03-10 |
PS
Planned sale
|
Dier Mardi
SVP and CFO
Officer
|
258
-2.4%
323.04
USD 83,344
|
258
-2.4%
|
323.04
|
USD 83,344
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
1,412
-27.5%
344.76
USD 486,797
|
1,412
-27.5%
|
344.76
|
USD 486,797
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
4,701
-47.8%
343.85
USD 1,616,429
|
4,701
-47.8%
|
343.85
|
USD 1,616,429
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
1,077
-9.9%
342.90
USD 369,300
|
1,077
-9.9%
|
342.90
|
USD 369,300
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
1,043
-8.7%
341.84
USD 356,537
|
1,043
-8.7%
|
341.84
|
USD 356,537
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
1,657
-12.2%
340.75
USD 564,627
|
1,657
-12.2%
|
340.75
|
USD 564,627
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Officer
|
400
-2.9%
339.68
USD 135,874
|
400
-2.9%
|
339.68
|
USD 135,874
|
|
